Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Steenokkerzeel – page 34

1 955 clinical trials in Steenokkerzeel, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steenokkerzeel at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Steenokkerzeel

Open in trial search

Study of ENTR-601-45 Safety and Effectiveness in Patients with Duchenne Muscular Dystrophy Who Can Skip Exon 45

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-45
  • Sponsor:Entrada Therapeutics Inc.

Study of 18F-AlF-FAPI-74 PET/CT imaging compared to standard 18F-FDG PET/CT in patients with fever of unknown origin, IgG4-related disease, and axial spondyloarthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of clopidogrel and acetylsalicylic acid (aspirin) for prevention of cardiovascular events in patients who survived intracerebral hemorrhage stroke

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University Of Edinburgh

Study on the Safety and Effectiveness of Emicizumab for Patients with TYPE 3 Von Willebrand Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:F. Hoffmann-La Roche AG

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Study on Long-term Safety and Efficacy of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Narcolepsy+1

Recruiting

Long-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Study of ENTR-601-44 in Children with Duchenne Muscular Dystrophy Who Are Eligible for Exon 44 Skipping Treatment

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:ENTR-601-44
  • Sponsor:Entrada Therapeutics Inc.

Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Alagille syndrome+1

Recruiting

Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Maralixibat
  • Sponsor:Mirum Pharmaceuticals Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Steenokkerzeel

What the registry says about research in the country

01 Multiple Sclerosis Research

Innovative clinical trials focusing on relapsing multiple sclerosis, evaluating the effectiveness of new therapeutic compounds compared to established treatments.

  • Treatment Comparison Studies
  • Relapse Reduction Research
  • Safety Assessment Protocols

These studies aim to advance treatment options for patients experiencing MS relapses.

02 Progressive MS Studies

Specialized research examining nonrelapsing secondary progressive multiple sclerosis, with emphasis on disability progression prevention.

  • Disease Progression Analysis
  • Novel Therapeutic Approaches
  • Long-term Disability Management

Current trials are exploring innovative treatments to slow disease advancement.

03 Remyelination Research

Groundbreaking studies investigating brain remyelination and neurodegeneration in progressive multiple sclerosis using established medications in new applications.

  • Walking Speed Assessment
  • Disease Progression Markers
  • Alternative Treatment Applications

Research focuses on long-term treatment outcomes over 96-week periods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.